ClinicalTrialsFinder
TerminatedPhase 4ACTRN12613001362785

Do new blood-thinning treatments commenced after cardiac surgery keep By-Pass Grafts open longer ?

The effect of postoperative Aspirin and Clopidogrel versus Aspirin and Ticagrelor on coronary graft patency in patients undergoing primary isolated coronary artery bypass surgery (CABG) post acute coronary syndrome (ACS) presentation

Sponsor

Waikato District Health Board

Enrollment

400 participants

Start Date

Aug 7, 2014

Study Type

Interventional

Conditions

Coronary Artery Graft Patency following Coronary Artery Bypass Graft (CABG) post Acute Coronary Syndrome (ACS)

Summary

By pass grafts fail following cardiac surgery in nearly one in five people at 12 months .New blood thinning medicines may reduce the likelihood of this happening.In this trial we will look at these agents and whether or not they keep by pass grafts open with CT scan assessment of the by passes at 12 months

Eligibility

Sex: Both males and females

Inclusion Criteria1

  • Patients undergoing primary isolated CABG post ACS presentation

Exclusion Criteria5

  • Previous CABG
  • Platelet count <100x 109/l
  • need for concomitant valve surgery or aneurysm resection
  • Need for post op warfarin
  • profuse post op bleeding

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

All patients who are undergoing isolated CABG following an ACS presentation at Waikato hospital Hamilton NZ and the Austin hospital Melbourne Australia will be eligible for randomisation and will be a

All patients who are undergoing isolated CABG following an ACS presentation at Waikato hospital Hamilton NZ and the Austin hospital Melbourne Australia will be eligible for randomisation and will be approached to consider participation After CABG patients will be randomised to receive enteric coated Aspirin 100 mg orally daily and either Ticagrelor 90 mg orally twice daily or Clopidogrel 75 mg orally daily for 12 months post CABG. Post-operatively dual anti-platelet treatment will be commenced within 12 hours of the procedure, once the cardiac surgeon assessment indicates bleeding /drainage is less that 50 ml/hour The study drug initial dose after surgery is going to be the maintenance dose, 75 mg orally daily for clopidogrel and 90 mg orally twice dailiy for ticagrelor. Compliance will be assessed by phone follow up

Locations(2)

Austin Health - Austin Hospital - Heidelberg

VIC, Australia

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12613001362785